No Difference in Aprepitant vs Fosaprepitant in CINV

Share this content:
This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.
This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.
The following article features coverage from the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Anaheim, California. Click here to read more of Cancer Therapy Advisor's conference coverage.

Aprepitant and fosaprepitant have similar efficacy and safety profiles for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), according to a poster presented at the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference.1

Current guidelines recommend an NK1 receptor antagonist, a serotonin (5-HT3) receptor antagonist, and dexamethasone for the prevention and treatment of CINV among patients taking highly or moderately emetogenic chemotherapy. The guidelines do not indicate a preference between the NK1 receptor antagonists, aprepitant or fosaprepitant. The aim of this study was to determine the comparative efficacy of these agents.

This retrospective cohort study of 41 patients included patients with various cancer types receiving chemotherapy at the University of New Mexico Comprehensive Cancer Center during 2015.

Treatment with aprepitant or fosaprepitant resulted in similar outcomes, with no significant difference in complete response (43.9% vs 41.5%), emesis (14.6% vs 17.1%), nausea (53.7% vs 58.8%), or need for rescue medication (56.1% vs 58.5%).

Aprepitant use required significantly less chair time (214.66 min) compared with fosaprepitant (233.49 min; P < .001).

The rate of adverse effects including constipation, fatigue, diarrhea, anxiety, headache, dizziness, xerostomia, and cough, were similar between the studied groups.

RELATED: Dronabinol Oral Solution Approved for CINV

The results of this study indicate that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.

Read more of Cancer Therapy Advisor's coverage of the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference by visiting the conference page.

Reference

  1. Case B, Anselmo L, Marshik P, Sanchez L. Aprepitant versus fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting. Poster presented at: 13th Hematology/Oncology Pharmacy Association Annual Conference; March 29-April 1, 2017; Anaheim, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs